格隆汇8月19日｜申联生物(688098.SH)今日再度20CM涨停，为连续第三日涨停，报价15.4元，创2021年 3月以来新高。 申联生物昨晚发布股票交易异常波动公告称，经公司自查，并发函向控股股东、实际控 制人核实，截至本公告披露日，公司不存在应披露而未披露的重大事项。公司目前生产经营正常，生产 经营未发生重大变化。公司目前的主营业务是兽用生物制品，艾滋病单克隆抗体等创新药管线由联营公 司扬州世之源生物科技有限责任公司独立运营，相关业务具有研发周期长，投入大，研发风险高的特 点。 ...

Group 1 - The company's stock price has experienced an abnormal fluctuation, with a cumulative increase of over 30% in closing prices over three consecutive trading days [1] - The main business of the company is focused on veterinary biological products, while the innovative drug pipeline, including HIV monoclonal antibodies, is independently operated by its joint venture, Yangzhou Shizhi Source Biotechnology Co., Ltd. [1] - The related business has characteristics of long research and development cycles, high investment, and significant research risks [1]

Group 1 - The company's stock price has experienced an abnormal fluctuation, with a cumulative increase of over 30% in closing prices over three consecutive trading days [1] - The main business of the company is focused on veterinary biological products, while the innovative drug pipeline, including HIV monoclonal antibodies, is independently operated by its joint venture, Yangzhou Shizhi Source Biotechnology Co., Ltd. [1] - The related business has characteristics of long research and development cycles, high investment, and significant research risks [1]

Group 1 - The core business of the company is veterinary biological products, while the innovative drug pipeline, including AIDS monoclonal antibodies, is independently operated by its joint venture, Yangzhou Shizhi Source Biotechnology Co., Ltd. [2] - The related business has characteristics of long research and development cycles, high investment, and significant research risks [2]

Group 1 - The company, Shenlian Bio, has issued a notice regarding its business operations, which primarily focus on veterinary biological products [2] - The innovative drug pipeline, including monoclonal antibodies for HIV, is independently operated by its joint venture, Yangzhou Shizhiyuan Biotechnology Co., Ltd [2] - The related business is characterized by long research and development cycles, significant investment, and high research risks [2]